SG10201804817TA - Delayed release compositions of linaclotide - Google Patents

Delayed release compositions of linaclotide

Info

Publication number
SG10201804817TA
SG10201804817TA SG10201804817TA SG10201804817TA SG10201804817TA SG 10201804817T A SG10201804817T A SG 10201804817TA SG 10201804817T A SG10201804817T A SG 10201804817TA SG 10201804817T A SG10201804817T A SG 10201804817TA SG 10201804817T A SG10201804817T A SG 10201804817TA
Authority
SG
Singapore
Prior art keywords
linaclotide
delayed release
release compositions
compositions
processes
Prior art date
Application number
SG10201804817TA
Inventor
Angelika Fretzen
Mark Currie
Ahmad Hashash
Mahendra Dedhiya
Yun Mo
Anil Chhettry
Matthew Miller
Ritesh Sanghvi
Mohammad Bari
Andreas Grill
Original Assignee
Ironwood Pharmaceuticals Inc
Forest Laboratories Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52293217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201804817T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc, Forest Laboratories Holdings Ltd filed Critical Ironwood Pharmaceuticals Inc
Publication of SG10201804817TA publication Critical patent/SG10201804817TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

DELAYED RELEASE COMPOSITIONS OF LINACLOTIDE The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions. [No Suitable figure]
SG10201804817TA 2013-12-11 2014-12-11 Delayed release compositions of linaclotide SG10201804817TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361914951P 2013-12-11 2013-12-11
US201361914952P 2013-12-11 2013-12-11

Publications (1)

Publication Number Publication Date
SG10201804817TA true SG10201804817TA (en) 2018-07-30

Family

ID=52293217

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201804817TA SG10201804817TA (en) 2013-12-11 2014-12-11 Delayed release compositions of linaclotide
SG11201604729QA SG11201604729QA (en) 2013-12-11 2014-12-11 Delayed release compositions of linaclotide

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201604729QA SG11201604729QA (en) 2013-12-11 2014-12-11 Delayed release compositions of linaclotide

Country Status (29)

Country Link
US (7) US20160310559A1 (en)
EP (2) EP3821881A1 (en)
JP (4) JP6964380B2 (en)
KR (3) KR102509291B1 (en)
CN (3) CN115089556A (en)
AU (3) AU2014362220B2 (en)
BR (1) BR112016013419A2 (en)
CA (1) CA2933587C (en)
CL (1) CL2016001424A1 (en)
CY (1) CY1123953T1 (en)
DK (1) DK3079669T3 (en)
EA (1) EA201691216A1 (en)
EC (2) ECSP16059106A (en)
ES (1) ES2838007T3 (en)
HR (1) HRP20201753T1 (en)
HU (1) HUE052981T2 (en)
IL (2) IL246155A0 (en)
LT (1) LT3079669T (en)
MX (2) MX2016007625A (en)
NZ (2) NZ721952A (en)
PE (2) PE20161373A1 (en)
PH (1) PH12016501122A1 (en)
PL (1) PL3079669T3 (en)
PT (1) PT3079669T (en)
RS (1) RS61133B1 (en)
SG (2) SG10201804817TA (en)
SI (1) SI3079669T1 (en)
UA (1) UA119335C2 (en)
WO (2) WO2015089326A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119335C2 (en) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Delayed release compositions of linaclotide
AR101476A1 (en) 2014-08-07 2016-12-21 Acerta Pharma Bv METHODS TO TREAT CANCER, IMMUNE AND AUTO-IMMUNE DISEASES, AND INFLAMMATORY DISEASES BASED ON THE OCCUPATION RATE OF THE BRUTON TYPOSIN QUINASE (BTK) AND THE RESULTS OF THE TIROSIN QUINASK (TUTOSIN QUINASK)
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US20180008547A1 (en) * 2015-02-02 2018-01-11 Aurobindo Pharma Ltd Stable Compositions comprising Linaclotide
JP2018516937A (en) * 2015-06-05 2018-06-28 アイアンウッド ファーマシューティカルズ インコーポレイテッド Modified or targeted release formulation of linaclotide
WO2017156214A1 (en) * 2016-03-11 2017-09-14 Gateway Pharmaceutical LLC Pharmaceutical compositions for colon-specific delivery
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
WO2018065826A1 (en) * 2016-10-06 2018-04-12 Sucampo Ag Multilayer beads for pharmaceutical use
MA47112A (en) * 2016-12-21 2019-10-30 Ironwood Pharmaceuticals Inc METHODS FOR TREATING IRRITABLE COLON SYNDROME WITH MODIFIED OR DELAYED LINACLOTIDE RELEASE FORMULATIONS
KR102227486B1 (en) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 Oral solid formulation composition comprising proton pump inhibitor, oral solid formulation comprising the same and manufacturing method thereof
EA202092275A1 (en) * 2018-03-23 2021-02-09 Палатин Текнолоджиз, Инк. COMPOSITIONS OF PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR AND METHODS OF DELIVERY TO THE GASTROINTESTINAL TRACT
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
JP2022536494A (en) * 2019-06-10 2022-08-17 アイアンウッド ファーマシューティカルズ， インコーポレイテッド Treatment of abdominal pain associated with diarrhea-type irritable bowel syndrome
KR102104507B1 (en) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same
CN110935007B (en) * 2019-12-12 2023-06-23 烟台大学 Linaclotide compound composition, preparation, application and preparation method thereof
EP4340838A1 (en) * 2021-05-19 2024-03-27 Alberto Paz Orally administered compositions for cancer treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN201252259Y (en) * 2008-07-24 2009-06-03 富士康(昆山)电脑接插件有限公司 Electrical connector
KR20210145307A (en) * 2008-08-15 2021-12-01 아이언우드 파마슈티컬스, 인코포레이티드 Linaclotide-containing formulations for oral administration
EP2373296B1 (en) * 2008-12-03 2016-08-03 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
WO2011017502A2 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
US20130045239A1 (en) * 2009-08-13 2013-02-21 Ironwood Pharmaceuticals, Inc. Method for Modulating the Pharmacodynamic Effect of Orally Administered Guanylate Cyclase Receptor Agonists
AU2011218009B2 (en) * 2010-02-17 2016-11-03 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
PT2603232T (en) * 2010-08-11 2020-01-09 Ironwood Pharmaceuticals Inc Stable formulations of linaclotide
CN103702678A (en) * 2010-09-11 2014-04-02 硬木药品公司 Treatment of constipation-predominant irritable bowel syndrome
JP2012155108A (en) * 2011-01-26 2012-08-16 Kyocera Document Solutions Inc Developing roller, developing device and image forming apparatus
DK2776055T3 (en) * 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
BR112014007753B1 (en) * 2011-09-30 2021-07-06 Astellas Pharma Inc. granular pharmaceutical composition, formulation and method for production
US20140018307A1 (en) * 2012-07-12 2014-01-16 Forest Laboratories Holdings Ltd. Linaclotide compositions
AU2014218599C1 (en) * 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
UA119335C2 (en) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Delayed release compositions of linaclotide

Also Published As

Publication number Publication date
AU2014362220A1 (en) 2016-06-30
UA119335C2 (en) 2019-06-10
NZ721952A (en) 2022-05-27
EP3079669A1 (en) 2016-10-19
WO2015089335A1 (en) 2015-06-18
PL3079669T3 (en) 2021-04-06
PE20161373A1 (en) 2016-12-17
HRP20201753T1 (en) 2020-12-25
US20240075094A1 (en) 2024-03-07
KR20210152588A (en) 2021-12-15
AU2020202319A1 (en) 2020-04-23
KR20160132001A (en) 2016-11-16
JP2023126475A (en) 2023-09-07
SI3079669T1 (en) 2021-01-29
US20220031802A1 (en) 2022-02-03
ES2838007T3 (en) 2021-07-01
AU2020202319B2 (en) 2022-03-24
HUE052981T2 (en) 2021-05-28
JP2021113227A (en) 2021-08-05
JP6964380B2 (en) 2021-11-10
KR20230039764A (en) 2023-03-21
JP2017504590A (en) 2017-02-09
PT3079669T (en) 2020-11-30
BR112016013419A2 (en) 2017-09-26
DK3079669T3 (en) 2020-11-02
PH12016501122A1 (en) 2016-07-18
US20160310559A1 (en) 2016-10-27
CN112569199A (en) 2021-03-30
ECSP21072161A (en) 2021-11-18
WO2015089326A1 (en) 2015-06-18
NZ759512A (en) 2022-05-27
CA2933587A1 (en) 2015-06-18
MX2016007625A (en) 2016-12-09
US20180015139A1 (en) 2018-01-18
EP3821881A1 (en) 2021-05-19
US20170157200A1 (en) 2017-06-08
CN106659687A (en) 2017-05-10
MX2021011906A (en) 2021-10-26
ECSP16059106A (en) 2017-02-24
CL2016001424A1 (en) 2017-09-08
JP2019073559A (en) 2019-05-16
KR102509291B1 (en) 2023-03-14
RS61133B1 (en) 2020-12-31
CY1123953T1 (en) 2022-03-24
CN115089556A (en) 2022-09-23
EP3079669B1 (en) 2020-09-30
AU2014362220B2 (en) 2020-04-30
US20160310560A1 (en) 2016-10-27
PE20211976A1 (en) 2021-10-05
EA201691216A1 (en) 2016-11-30
WO2015089326A9 (en) 2016-08-04
SG11201604729QA (en) 2016-07-28
IL283012A (en) 2021-06-30
US20200038476A1 (en) 2020-02-06
CA2933587C (en) 2023-09-26
AU2022201891A1 (en) 2022-04-07
IL246155A0 (en) 2016-07-31
KR102337809B1 (en) 2021-12-10
LT3079669T (en) 2020-12-10

Similar Documents

Publication Publication Date Title
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX348823B (en) Stable formulations of linaclotide.
MX363347B (en) Salt of omecamtiv mecarbil and process for preparing salt.
UA115357C2 (en) Pyridin-4-yl derivatives
EP3074000A4 (en) Suspension compositions of physiologically active phenolic compounds&methods of making and using the same
WO2014153495A3 (en) Novel stat3 inhibitors
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
WO2015092810A3 (en) Amorphous form of idelalisib
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
MX2015000179A (en) Itraconazole compositions and dosage forms, and methods of using the same.
MX2015016603A (en) Corticosteroid compositions.
WO2014155389A3 (en) Process for preparation of ticagrelor
WO2015087343A3 (en) An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof
MX367773B (en) Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof.
EP3040337A4 (en) 2, 6-di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
WO2014122671A3 (en) Solid oral compositions of saxagliptin
IN2013CH04314A (en)
IN2013CH04330A (en)
MX2016002186A (en) Process for preparing dronedarone and salts thereof.
IN2013MU01226A (en)
MX2012014969A (en) Stable pharmaceutical compositions comprising amlodipine and telemisartan.